Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.
View Top Employees from Immunomic Therapeutics, Inc.| Website | http://www.immunomix.com |
| Revenue | $5 million |
| Funding | $83.5 million |
| Employees | 44 (44 on RocketReach) |
| Founded | 2005 |
| Address | 15010 Broschart Road Suite 250, Rockville, Maryland 20850, US |
| Phone | (301) 968-3501 |
| Technologies |
JavaScript,
HTML,
PHP
+19 more
(view full list)
|
| Industry | Biotechnology, DNA Vaccines, Pharmaceuticals, Science and Engineering, LAMP Technology, Healthcare, Life Science, Allergy, Therapeutics, Oncology, Health Care, Animal Health, Infectious Diseases |
| Competitors | Altimmune, Inc., Angiochem, Mologen AG (MGN), Profectus BioSciences, Inc, Vaxart, Inc. |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies |
Looking for a particular Immunomic Therapeutics, Inc. employee's phone or email?
Immunomic Therapeutics, Inc. Questions
The Immunomic Therapeutics, Inc. annual revenue was $5 million in 2024.
44 people are employed at Immunomic Therapeutics, Inc..
Immunomic Therapeutics, Inc. is based in Rockville, Maryland.
The NAICS codes for Immunomic Therapeutics, Inc. are [541, 54, 5417].
The SIC codes for Immunomic Therapeutics, Inc. are [283, 28].
Top Immunomic Therapeutics, Inc. Employees
-
5+5+
-
32
-
55+
-
ViewScott Rodgers
Vice President Clinical Operations at Immunomic Therapeutics, Inc.
Gaithersburg, MD, US5+5+ -
5+5+
-
35+
-
3
-
21
Related Companies
